Predicting survival in malignant pleural effusion: Development and validation of the LENT prognostic score

Thorax

Volumn 69, Issue 12, 2014, Pages 1098-1104

  Clive, Amelia O ^a   Kahan, Brennan C ^b   Hooper, Clare E ^a   Bhatnagar, Rahul ^a   Morley, Anna J ^a   Zahan Evans, Natalie ^a   Bintcliffe, Oliver J ^a   Boshuizen, Rogier C ^c   Fysh, Edward T H ^d,e   Tobin, Claire L ^d   Medford, Andrew R L ^a   Harvey, John E ^a   Van Den Heuvel, Michel M ^c   Lee, Y C Gary ^d,e   Maskell, Nick A ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CLINICAL DECISION MAKING; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE SCORE; FEMALE; HIGH RISK POPULATION; HUMAN; LENT SCORE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT PLEURA EFFUSION; MODERATE RISK POPULATION; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PLEURA FLUID; PROGNOSTIC ASSESSMENT; RECEIVER OPERATING CHARACTERISTIC; RISK; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL PREDICTION; SURVIVAL TIME; VALIDATION PROCESS; VERY ELDERLY; AUSTRALIA; CLINICAL TRIAL; EPIDEMIOLOGY; FACTUAL DATABASE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NETHERLANDS; PLEURAL EFFUSION, MALIGNANT; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; UNITED KINGDOM; VALIDATION STUDY;

AGED; AGED, 80 AND OVER; AUSTRALIA; BIOMARKERS, TUMOR; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; GREAT BRITAIN; HUMANS; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; NETHERLANDS; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84919717552     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-205285     Document Type: Article

References (25)

1. The American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000;162:1987-2001.
2. Cancer Statistics Registrations, England (Series MB1): Office of National Statistics, Stationary Office, 2010.
3. Roberts ME, Neville E, Berrisford RG, et al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65(Suppl 2):ii32-40.
4. Tan C, Sedrakyan A, Browne J, et al. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 2006;29:829-38.
5. Pilling JE, Dusmet ME, Ladas G, et al. Prognostic factors for survival after surgical palliation of malignant pleural effusion. J Thorac Oncol 2010;5:1544-50.
6. Bielsa S, Salud A, Martinez M, et al. Prognostic signifi cance of pleural fluid data in patients with malignant effusion. Eur J Intern Med 2008;19:334-9.
7. Ozyurtkan MO, Balci AE, Cakmak M. Predictors of mortality within three months in the patients with malignant pleural effusion. Eur J Intern Med 2010;21:30-4.
8. Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000;117:73-8.
9. Pinato DJ, Mauri FA, Ramakrishnan R, et al. In flammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol 2012;7:587-94.
10. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011;47:2633-41.
11. Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010;16:5805-13.
12. Anevlavis S, Kouliatsis G, Sotiriou I, et al. Prognostic factors in patients presenting with pleural effusion revealing malignancy. Respiration 2014;87:311-6.
13. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377-99.
14. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999;28:964-74.
15. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
16. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid ph as a predictor of survival for patients with malignant pleural effusions. Chest 2000;117:79-86.
17. Martinez-Moragon E, Aparicio J, Sanchis J, et al. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 1998;65:108-13.
18. Suzuki K, Kadota K, Sima CS, et al. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol Immunother 2011;60:1721-8.
19. Li MX, Liu XM, Zhang XF, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 2014;134:2403-13.
20. Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 2012;307:2383-9.
21. Dresler CM, Olak J, Herndon JE II, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005;127:909-15.
22. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145-52.
23. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-31.
24. Putnam JB Jr, Walsh GL, Swisher SG, et al. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. Ann Thorac Surg 2000;69:369-75.
25. Kahan BC, Morris TP. Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis. BMJ 2012;345:e5840.